Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Rgenix Announces $33M Series B Financing To Develop First-in-Class Cancer Therapeutics

by businesswire.com posted 1year ago 708 views
Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, secures $33 Million in Series B Financing to develop cancer therapeutics.

In this article